二甲双胍联合沙格列汀或格列美脲对新诊断合并腹型肥胖的2型糖尿病患者临床疗效对比(1)
摘 要：目的 比較二甲双胍联合沙格列汀或者格列美脲在新诊断合并腹型肥胖的2型糖尿病患者疗效与安全性。方法 选取2017年4月～11月在我院就诊新诊断合并腹型肥胖的T2DM患者100例，每组50例。采用随机数字表法分为实验组和对照组，实验组给予二甲双胍联合沙格列汀治疗，对照组给予以二甲双胍联合格列美脲治疗。比较两组FPG、2hPPG、HbA1C、FINS、HOMA-β，评估两组患者腰围(WC)、BMI、血压、血脂改善情况及服药期间低血糖发生情况。结果 91例患者完成治疗随访，其中对照组45例，实验组46例。与治疗前相比，两组患者HbA1C、FPG、PPG均降低(P<0.05)，但两组间比较，差异有统计学意义(P>0.05);与治疗前相比，两组FINS、HOMA-β升高(P<0.05)。与对照组相比，实验组FINS、HOMA-β有改善(P<0.05)。治疗后，患者BMI、SBP、DBP、TG、LDL-C等指标比较，差异有统计学意义(P>0.05)。治疗后实验组WC呈现降低趋势，而对照组均有不同程度的升高;与对照组比较，实验组治疗后WC降低(P<0.05)，治疗期间实验组患者低血糖发生率(4.34%)低于对照组(20.00%)(P<0.05)。两组均无严重不良事件发生。结论 对新诊断的合并腹型肥胖的T2DM患者，二甲双胍联合沙格列汀与二甲双胍联合格列美脲降糖疗效相当，但沙格列汀在缩小低腰围及改善胰岛功能方面具有优势，同时具有较低的低血糖发生率。
, 百拇医药
关键词：2型糖尿病;腹型肥胖;糖化血红蛋白;胰岛功能;沙格列汀;格列美脲
中图分类号：R587.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.24.018
文章编号：1006-1959(2018)24-0070-04
Abstract：Objective To compare the efficacy and safety of metformin combined with salglutin or glimepiride in newly diagnosed type 2 diabetic patients with abdominal obesity.Methods A total of 100 T2DM patients with abdominal obesity were selected from April to November 2017 in our hospital，50 patients in each group.And were divided into the experimental group and the control group according to the random digital table.The experimental group was treated with metformin combined with salgletine， and the control group with metformin combined with glimepiride.We Compared the FPG，2hPPG，HbA1C，FINS，HOMA-β of the two groups，and waistline(WC)， BMI， blood pressure， blood lipid improvement and hypoglycemia were evaluated in both groups.Results 91 cases were followed up， including 45 cases in control group and 46 cases in experimental group.Compared with before treatment， HbA1C，FPG，PPG in both groups was lower than that before treatment (P<0.05)， but there was no significant difference between the two groups(P>0.05).Compared with before treatment， FINS，HOMA-β increased in both groups (P<0.05).Compared with the control group， FINS，HOMA-β in the experimental group was improved (P<0.05). After treatment，the change of BMI，SBP，DBP，TG，LDL-C and other indexes were compared(P>0.05).After treatment， the WC of the experimental group showed a decreasing trend， while the control group had different degrees of increase. Compared with the control group， the WC of the experimental group decreased after treatment (P<0.05)， and the incidence of hypoglycemia in the experimental group during the treatment period (4.34%). It was lower than the control group (20.00%) (P<0.05). There were no serious adverse events in either group. Conclusion For newly diagnosed patients with T2DM with abdominal obesity， metformin combined with saxagliptin is equivalent to metformin combined with glimepiride， but saxagliptin has advantages in reducing low waist circumference and improving islet function. Lower incidence of hypoglycemia., 百拇医药(廖霜)
, 百拇医药
关键词：2型糖尿病;腹型肥胖;糖化血红蛋白;胰岛功能;沙格列汀;格列美脲
中图分类号：R587.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.24.018
文章编号：1006-1959(2018)24-0070-04
Abstract：Objective To compare the efficacy and safety of metformin combined with salglutin or glimepiride in newly diagnosed type 2 diabetic patients with abdominal obesity.Methods A total of 100 T2DM patients with abdominal obesity were selected from April to November 2017 in our hospital，50 patients in each group.And were divided into the experimental group and the control group according to the random digital table.The experimental group was treated with metformin combined with salgletine， and the control group with metformin combined with glimepiride.We Compared the FPG，2hPPG，HbA1C，FINS，HOMA-β of the two groups，and waistline(WC)， BMI， blood pressure， blood lipid improvement and hypoglycemia were evaluated in both groups.Results 91 cases were followed up， including 45 cases in control group and 46 cases in experimental group.Compared with before treatment， HbA1C，FPG，PPG in both groups was lower than that before treatment (P<0.05)， but there was no significant difference between the two groups(P>0.05).Compared with before treatment， FINS，HOMA-β increased in both groups (P<0.05).Compared with the control group， FINS，HOMA-β in the experimental group was improved (P<0.05). After treatment，the change of BMI，SBP，DBP，TG，LDL-C and other indexes were compared(P>0.05).After treatment， the WC of the experimental group showed a decreasing trend， while the control group had different degrees of increase. Compared with the control group， the WC of the experimental group decreased after treatment (P<0.05)， and the incidence of hypoglycemia in the experimental group during the treatment period (4.34%). It was lower than the control group (20.00%) (P<0.05). There were no serious adverse events in either group. Conclusion For newly diagnosed patients with T2DM with abdominal obesity， metformin combined with saxagliptin is equivalent to metformin combined with glimepiride， but saxagliptin has advantages in reducing low waist circumference and improving islet function. Lower incidence of hypoglycemia., 百拇医药(廖霜)